ArticleEuropean journal of medical research2026
Correlation between albumin-bilirubin score and comorbidity of cardiovascular disease and chronic kidney disease: insights from NHANES 2011-2018.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrowing evidence indicates that cardiovascular disease (CVD), chronic kidney disease (CKD), and liver dysfunction share common pathophysiological pathways and constitute an interconnected syndrome. The albumin-bilirubin (ALBI) score, originally developed to assess liver function, has shown prognostic value in various nonhepatic diseases. However, its association with the comorbidity of CVD and CKD remains unclear. This study aimed to investigate the association between ALBI score and CVD-CKD comorbidity and to explore potential intermediate factors in a nationally representative US adult population.
methodsA cross-sectional analysis of 15,681 adults from the National Health and Nutrition Examination Survey (NHANES) 2011-2018 was conducted. The ALBI score was calculated as: (log10 bilirubin [μmol/L] × 0.66) + (albumin [g/L] × - 0.085). Weighted multivariable logistic regression, restricted cubic spline, threshold effect, subgroup, and mediation analyses were performed.
resultsAfter fully adjusting for confounders (age, sex, race, education level, poverty-income ratio, body mass index, hypertension, smoking, alcohol use, and diabetes), each one-unit increase in the ALBI score was associated with more than a 4.38-fold higher prevalence of cardiovascular disease-chronic kidney disease (CVD-CKD) comorbidity (OR = 5.38, 95% CI 3.84-7.54; P < 0.001). A nonlinear relationship was observed (nonlinearity test P < 0.001), with an inflection point at approximately - 3.436. Exploratory mediation analyses indicated that diabetes and the body roundness index (BRI) statistically accounted for about 5%-6% and 0.5% of the association, respectively. However, the proportion explained by reverse mediation (diabetes → ALBI → CVD-CKD) was larger, reaching up to 6.3%.
conclusionHigher ALBI score is independently associated with increased odds of CVD-CKD comorbidity. The association appears to be largely driven by shared metabolic disturbances rather than liver dysfunction being upstream of diabetes or obesity. ALBI may serve as a simple, objective marker for early risk stratification in the cardiovascular-kidney-metabolic axis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.